Skip to main content
. 2017 May 4;14(1):306–312. doi: 10.3892/ol.2017.6118

Figure 2.

Figure 2.

Correlations were assessed between previous gefitinib therapy and the progression free survival of erlotinib therapy. (A) Correlation between the PFS of erlotinib and the PFS of gefitinib. (B) Correlation between the PFS of erlotinib against the interval from gefitinib to erlotinib. PFS, progression free survival.